Nanobiotix Announces Launch of Global Follow-On Offering

NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the launch, subject to market and other conditions, of an approximately €75 million global follow-on offering (representing approximately $87 million) consisting of (i) a public offering of its American Depositary Shares (“ ADSs ”), each ADS representing one ordinary share, €0.03 nominal value per share (each an “ Ordinary Share ”), of the Company, in the United States (the “ U.S. Offering ”) and (ii) an offering of (a) its Ordinary Shares and (b) pre-funded warrants to subscribe for Ordinary Shares (the “ PFW ”), exclusively addressed to “qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended (the “ Prospectus Regulation ”), and certain other countries (excluding the United States and Canada) (the “ International Offering ”). The U.S. Offering and the International Offering are referred to, together, as the “ Global Offering ”. The number of ADSs and Ordinary Shares issued in the Global Offering may be increased in the event of significant demand.